Targeted therapy for short QT syndrome.
Identified in 2000, short QT syndrome is an electrical disease of the heart characterised as a channelopathy. At first considered extremely rare, families with this disease have been found in Brazil, Finland, Germany, Spain, the Netherlands, France, Turkey, Italy and the US. The focus of the paper is to present a current review of short QT syndrome, as well as providing an overview upon the potential molecular target-based strategies for management of this very deadly disease. Abnormalities in three different potassium channels have been recognised as the cause of the disease and targets for therapy will be discussed for each potassium channel individually. In addition to pharmacological strategies, gene therapy with transfer of genes coding for specific ion channel subunits or regulatory proteins are discussed.
Bjerregaard
Preben
P
Division of Cardiology, Saint Louis University Hospital, Saint Louis, MO 63110, USA. bjerregp@slu.edu
Jahangir
Arshad
A
Gussak
Ihor
I
D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008133:Long QT Syndrome / Q000188:drug therapy / Q000503:physiopathology; D024642:Potassium Channels, Voltage-Gated / Q000502:physiology
D002317:Cardiovascular Agents; D024642:Potassium Channels, Voltage-Gated